Anti-PCSK9 Monoclonal Antibody for Hypercholesterolemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypercholesterolemia, such as statins, are ineffective for 8.2% of patients and fail to achieve desired cholesterol levels, and there is a need for novel immunotherapy antibodies that can specifically bind to PCSK9 to upregulate LDLR expression and enhance lipid metabolism.
Innovation Solution
Development of an anti-PCSK9 monoclonal antibody with specific modifications in its CDR regions, which binds to PCSK9, blocking its association with LDLR, thereby increasing LDLR expression on the cell surface, reducing LDL and triglyceride levels, and providing long-term efficacy in treating hypercholesterolemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If statins are used to treat hypercholesterolemia, then cholesterol levels are reduced in most patients, but 8.2% of patients cannot achieve desired cholesterol levels or are intolerant to statins
Solution Approach 1:
The patent changes the therapeutic approach from statin-mediated inhibition of HMG-CoA reductase to PCSK9 antibody-mediated blockade of PCSK9-LDLR interaction. This parameter change in the mechanism of action enables effective cholesterol reduction in patients who cannot respond to or tolerate statins, thereby expanding adaptability while maintaining reliability of the therapeutic effect.
2Reliability
If existing PCSK9 antibodies are administered, then LDL cholesterol levels are reduced, but the duration of efficacy is insufficient compared to the desired long-term effect
Solution Approach 1:
The patent modifies the duration parameter by engineering the antibody with an extended half-life through modifications to the Fc region, allowing the antibody to persist in circulation longer. This enables sustained blockade of PCSK9 and maintains therapeutic efficacy for extended periods, reducing the frequency of administration while preserving reliable LDL reduction.
3Reliability
If monoclonal antibodies are developed to bind PCSK9, then LDLR expression is upregulated and lipid metabolism is enhanced, but the complexity of antibody development and production increases
Solution Approach 1:
The patent changes the structural parameters of the antibody by humanizing non-human antibodies and modifying the Fc region for extended half-life. These controlled structural modifications maintain the essential specificity of PCSK9 binding while optimizing pharmacokinetic properties, achieving a balance between specificity and manageable complexity for production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-PCSK9 monoclonal antibody effectively reduces plasma LDL and triglyceride levels, offering prolonged efficacy in both mice and monkeys, surpassing the effects of existing antibodies like Evolocumab, and demonstrates potential in preventing and treating cardiovascular diseases caused by hypercholesterolemia.
Implementation Method 1
The inventors obtained an anti-PCSK9 monoclonal antibody. The inventors surprisingly found that the monoclonal antibody in the present invention can specifically bind to PCSK9, effectively block the association of PCSK9 and LDLR
Implementation Method 2
upregulate the amount of LDLR expressed on cell membrane, promote the metabolism of LDL cholesterol, and decrease the level of TG with a long half-life in particular
Data Source
AI summary
The present invention belongs to the field of immunology and molecular biology, which relates to an anti-PCSK9 antibody, the pharmaceutical composition and method of use thereof. In particular, the present invention relates to the monoclonal antibody, which can bind PCSK9 specifically, block association of PCSK9 with LDLR, upregulate the amount of LDLR on cell surface, heighten the metabolism of LDL cholesterol and/or triglycerides, and prevent/treat cardiovascular diseases caused by hypercholesterolemia.